TUDCA is a new generation of active substance
to dissolve cholesterol stone. Studies in recent years have shown that
it also has a variety of physiological functions such as protecting liver
cells, lowering yellow, lowering enzyme, immunoregulation and inhibiting
apoptosis of liver cells.
Camparing to UDCA ,TUDCA is highly ionized and
hydrophilic, and has high bioavailability in the intestinal liver circulation,
strong liver uptake capacity, and more bile acids, can promote bile excretion,
but have little damage to cells and strong cholagogue and liver protection.
Recent studies on patients after liver transplantation showed that, after the
application of TUDCA, liver cell enzymes (ALT, AST, GGT, ALP) were
significantly decreased, and total bile acid was significantly decreased in 5
and 9 months after the addition of TUDCA. In addition, it has good application
prospect for fatty liver, cirrhosis and liver cancer.
TUDCA and UDCA is a process which can
effectively inhibit the synthesis of liver cholesterol and promoting
cholesterol in the form of liquid crystal compounds cholesterol from the
gallbladder to intestinal excretion and reduce fat in the liver savings within
the organization, enhance the biological activities of catalase, increase the
detoxification function of liver tissue, but also significantly reduce the
levels of serum triglycerides.
In addition, TUDCA may delay the progression of
cirrhosis by inhibiting the expression of TGF- expression 1. 48 cases of
cirrhosis were randomly divided into TUDCA group and UDCA group. After 3 months
of treatment, the total bile acid and liver cell enzyme of the two groups were
significantly decreased and the mean value of serum albumin was significantly
increased (P<0.05). At 6 months of treatment, the mean values of serum
bilirubin, ALT, AST, ALP and GGT in TUDCA group decreased by 13.7%, 42.8%,
45.9%, 38.4% and 47.7%, respectively, and the mean values of serum albumin were
increased by 16.8%, among which serum AST, ALP, GGT and albumin were
significantly improved (P<0.05). Serum ALT, GGT and albumin levels were
significantly improved in UDCA group (P<0.05). At the end of treatment, ALP
and AST decreased significantly in the experimental group compared with the
control group (P<0.05). Therefore, TUDCA can improve the liver function
indicators of patients with cirrhosis, especially the level of cholestasis, and
may delay the progression of liver fibrosis in patients.
Liver cancer is a kind of cancer induced by
chronic inflammation. Studies show that inflammatory signal plays a decisive
role in the occurrence and development of liver cancer. One feature of liver
cancer is the accumulation of non-folding proteins in the endoplasmic reticulum
(ER), which leads to non-folding protein reactions (UPR). Endoplasmic reticulum
(ER) is an important organelle needed for cell survival. Highly sensitive to
changes in the internal balance of cells, disrupted ER balance will lead to
accumulation of unfolded proteins, thus interfering with ER function and
causing ER stress. TUDCA has been proved to play a protective role of cells by
reducing oxidative stress in different models, and ER stress is closely related
to oxidative stress. Other studies have shown that TUDCA can eliminate the
caspase-12 apoptosis process caused by ER stress and inhibit the activation and
apoptosis of the apoptosis-3/7 related factors. TUDCA can also reduce the
hepatotoxicity induced by carcinogens, and at least partially alleviate the
positive feedback, inflammatory response and apoptosis of endoplasmic reticulum
stress in liver tissues damaged by carcinogens, thus preventing the generation
of hepatocellular tumors.
没有评论:
发表评论